Biophytis modifies €2M Hexagon facility into revolving line, cuts rate to 10%
What's the deal? French biotech BiophytisDealroom has a profile for this one. Try Dealroom → has modified its financing agreement with Hexagon Capital Fund, establishing a renewable €2 million revolving credit facility and cutting its annual interest rate from 12% to 10%. The changes, finalised on May 22, 2026, allow the company to reissue up to 2,000 bonds upon repayment.
Why now? Biophytis is gearing up to launch a joint venture in Hong Kong to begin its Phase 3 sarcopenia study. It also has upcoming programmes in obesity. The restructured facility gives the company more financial flexibility to fund these clinical milestones.
What could go wrong? Biophytis remains a clinical-stage company dependent on external financing. A revolving facility helps with agility, but it doesn't eliminate the risk of needing further capital if trials run long or results disappoint.
The signal: Biophytis, classified by Dealroom as an "early growth" stage company, securing improved debt terms underscores a broader pattern in European biotech — clinical-stage firms increasingly leaning on structured debt facilities rather than dilutive equity to bridge funding gaps between trial milestones. The pivot toward a Hong Kong joint venture for its Phase 3 sarcopenia programme also reflects how smaller biotechs are looking to Asian markets to diversify both their clinical and financing strategies.
Read more: webdisclosure.com
